IP Verse

Anticancer Compositions

PatentPatent Analysis

EP3226841

ARAGON PHARMACEUTICALS
Application Number
EP15817641A
Filing Date
Dec 3, 2015
Status
Granted And Under Opposition
Sep 6, 2024
Grant Date
Oct 9, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3226843B1
EP3533792B1
EP3226842B1

Bibliography

The patent EP3226841B1 was granted to Aragon Pharmaceuticals on Oct 9, 2024 following the initial filing on Dec 3, 2015 under the application number EP15817641A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BRAND MURRAY FULLERJul 9, 2025ADMISSIBLE
EIPJul 9, 2025ADMISSIBLE
HEXALJul 9, 2025ADMISSIBLE
TEVA PHARMACEUTICALSJul 8, 2025ADMISSIBLE
HAMM & WITTKOPPJul 7, 2025ADMISSIBLE
ZENTIVA KSJul 7, 2025ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents